Investor Relations

Corporate Profile

Fractyl Health is a clinical-stage metabolic therapeutics company focused on pioneering new approaches to treat obesity and T2D. Our Revita® and Rejuva® platform candidates are designed to target root causes of metabolic diseases and break the pattern of metabolic disease treatment from chronic management to potentially prevent and reverse metabolic disease. Fractyl Health is based in Burlington, Massachusetts.

Corporate Presentation

Commercial Strategy Event

REMAIN-1 Midpoint Cohort One-Year Results

REVEAL-1 One-Year Results

Minimum 15 minutes delayed. Source: LSEG

News Releases

Fractyl Health to Participate in Upcoming September Investor Conferences

Sep 9, 2026

Fractyl Health to Host Virtual Commercial Strategy Day on Tuesday, September 1, 2026: The Potential Path to Commercializing Revita®, a Procedural Therapy for Post-GLP-1 Weight Maintenance

Aug 20, 2026

Fractyl Health Reports Second Quarter 2026 Financial Results and Business Updates

Aug 10, 2026

Events

Morgan Stanley 24th Annual Global Healthcare Conference

Sep 14, 2026 | 5:35 PM EDT

H.C. Wainwright 28th Annual Global Investment Conference

Sep 11, 2026 | 7:00 AM EDT

SEC Filings

Official notification to shareholders of matters to be brought to a vote ("Proxy")

Aug 24, 2026 | Form Type: DEF 14A

Aug 24, 2026

A preliminary proxy statement providing notification matters to be brought to a vote

Aug 14, 2026 | Form Type: PRE 14A

Aug 14, 2026

Investor Relations Contacts

Brian Luque, Head of Investor Relations and Corporate Development

Email: ir@fractyl.com
Phone: 951.206.1200